MTRI · InMed Pharmaceuticals Inc. · Documents

Nov 8

Registration statement S-1

Registration statement

Nov 2

Current report 8-K

Regulation FD disclosure

Oct 30

Current report 8-K Events of Oct 24

Entered into a material agreement, Unregistered sale of equity, Other events

Oct 27

Proxy statement DEF 14A Meeting Dec 19, 2023

Proxy statement

Oct 27

Proxy statement DEFA14A

Proxy statement

Oct 24

Current report 8-K

Regulation FD disclosure

Sep 29

Current report 8-K

Regulation FD disclosure

Sep 29

Annual report 10-K FY2023, ended Jun 30

Annual report for FY2023

Revenue $4.14M ▲ 279.6% Net loss $7.95M Diluted EPS -$3.25

Sep 29

Late filing notice NT 10-K

Late filing notice

Sep 25

Current report 8-K Events of Sep 22

Delisting notice or listing transfer

Sep 25

Current report 8-K

Other events

Sep 8

Current report 8-K Events of Sep 7

Regulation FD disclosure

Jul 24

Current report 8-K Events of Jul 21

Regulation FD disclosure

Jul 20

Current report 8-K

Regulation FD disclosure

Jun 22

Current report 8-K

Regulation FD disclosure

Jun 1

Current report 8-K

Regulation FD disclosure

May 25

Current report 8-K Events of May 24

Regulation FD disclosure

May 19

Current report 8-K Events of Mar 18

Regulation FD disclosure

May 16

Current report 8-K Events of May 15

Regulation FD disclosure

May 15

Quarterly report 10-Q FY2023 Q3, ended Mar 31

Quarterly report for FY2023 Q3

Revenue $1.03M ▲ 234.0% Net loss $2M Diluted EPS -$0.60

Mar 28

Current report 8-K

Regulation FD disclosure

Mar 14

Current report 8-K Events of Mar 13

Regulation FD disclosure

Mar 7

Current report 8-K Events of Mar 6

Regulation FD disclosure

Feb 21

Current report 8-K Events of Feb 17

Regulation FD disclosure

Feb 17

Quarterly report 10-Q FY2023 Q2, ended Dec 31

Quarterly report for FY2023 Q2

Revenue $469.78K ▲ 77.2% Net loss $2.1M Diluted EPS -$0.91

Feb 10

Late filing notice NT 10-Q

Late filing notice

Jan 10

Current report 8-K

Regulation FD disclosure

Dec 16

Current report 8-K Events of Dec 15

Shareholder vote results, Regulation FD disclosure

Dec 13

Current report 8-K

Entered into a material agreement, Director or officer change, or executive pay, Other events

Dec 13

Current report 8-K Events of Dec 8

Change of auditor

Dec 13

Current report 8-K

Other events

Dec 7

Registration statement S-1

Registration statement

Nov 22

Current report 8-K Events of Nov 21

Entered into a material agreement, Unregistered sale of equity, Other events

Nov 17

Current report 8-K Events of Nov 16

Regulation FD disclosure

Nov 17

Current report 8-K

Director or officer change, or executive pay, Regulation FD disclosure

Nov 15

Current report 8-K Events of Nov 11

Other events

Nov 14

Quarterly report 10-Q FY2023 Q1, ended Sep 30

Quarterly report for FY2023 Q1

Revenue $320.79K Net loss $3.51M Diluted EPS -$4.06

Oct 28

Proxy statement DEF 14A Meeting Dec 15, 2022

Proxy statement

Oct 28

Proxy statement DEFA14A

Proxy statement

Oct 26

Current report 8-K

Regulation FD disclosure

Oct 12

Registration statement S-1

Registration statement

Sep 29

Current report 8-K

Other events

Sep 28

Annual report 10-K/A Ended Jun 30

Annual report for the period ended Jun 30, 2022

Sep 23

Current report 8-K

Regulation FD disclosure

Sep 23

Annual report 10-K FY2022, ended Jun 30

Annual report for FY2022

Revenue $1.09M Net loss $18.6M Diluted EPS -$33.17

Sep 20

Current report 8-K Events of Sep 19

Regulation FD disclosure

Sep 14

Current report 8-K Events of Sep 9

Entered into a material agreement, Unregistered sale of equity, Other events

Sep 8

Current report 8-K

Regulation FD disclosure

Aug 26

Current report 8-K Events of Aug 19

Change to shareholders' rights, Regulation FD disclosure, Other events

Aug 11

Current report 8-K Events of Aug 10

Director or officer change, or executive pay, Regulation FD disclosure